Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Dexmedetomidine on the Heart Beat During Elective Surgery in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ASA Physical Status I-II~* Age 3 to 10yrs~* Elective surgical procedure requiring general anesthesia~* Use of dexmedetomidine acceptable to the staff anesthesiologist~* Un-premedicated~* Ability to read and understand English (parent/legal guardian(s) and child)~Exclusion Criteria:~* Long QT syndrome (LQTS)~* Cardiac disease or rhythm abnormalities~* Family history of LQTS or abnormal cardiac conduction~* Currently taking medications known to prolong QT~* Currently taking medications known to predispose to hypokalemia~* Known hypersensitivity to dexmedetomidine or other study medication~* Weight \< 5th centile or \> 95th centile for age~* Previously diagnosed hypokalemia~* Impaired renal or liver function~* Pre-operative anxiety requiring sedatives or opioids~* Refusal to participate

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine 0.25mcg/kg (Type: EXPERIMENTAL): 0.25mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
- Dexmedetomidine 0.5mcg/kg (Type: EXPERIMENTAL): 0.5mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
- Dexmedetomidine 0.75mcg/kg (Type: EXPERIMENTAL): 0.75mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
- Saline bolus (Type: SHAM_COMPARATOR): 10mL normal saline solution administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).